Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study

被引：0
|
作者：
Fiorillo, Loretta [1 ]
Becker, Emily [2 ]
de Lucas, Raul [3 ]
Belloni-Fortina, Anna [4 ]
Maes, Peter [5 ]
Oberoi, Rajneet K. [5 ]
Paris, Maria [5 ]
Zhang, Wendy [5 ]
Zhang, Zuoshun [5 ]
Arkin, Lisa
机构：
[1] Univ Alberta, Stollery Childrens Hosp, Edmonton, AB, Canada
[2] Driscoll Childrens Hosp, Corpus Christi, TX USA
[3] Hosp Univ La Paz PPDS, Madrid, Spain
[4] Azienda Osped Univ Padova, Padua, Italy
[5] Amgen Inc, Thousand Oaks, CA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42163
引用
下载
收藏
页码：AB122 / AB122
页数：1
相关论文
共 50 条
  • [21] Two phase 3 studies of oral tofacitinib in patients with moderate to severe plaque psoriasis: 16-week efficacy and safety results
    Papp, Kim A.
    Menter, Martin A.
    Abe, Masatoshi
    Elewski, Boni E.
    Feldman, Steven R.
    Gottlieb, Alice G.
    Thaci, Diamant
    Luger, Thomas
    Tatulych, Svitlana
    Gupta, Pankaj
    Proulx, James
    Lan, Shu-Ping
    Wolk, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB66 - AB66
  • [22] Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept
    Bagel, Jerry
    Lynde, Charles
    Tyring, Stephen
    Kricorian, Gregory
    Shi, Yifei
    Klekotka, Paul
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (01) : 86 - 92
  • [23] A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
    Cai, Lin
    Jiang, Congjun
    Zhang, Guoqiang
    Fang, Hong
    Wang, Jinyan
    Li, Yumei
    Xu, Hui
    Xiao, Rong
    Ding, Yangfeng
    Huang, Kun
    Zhang, Chunlei
    Zhang, Litao
    Chen, Bin
    Duan, Xinsuo
    Pan, Weili
    Han, Guangming
    Chen, Rongyi
    Liu, Lunfei
    Zhang, Shoumin
    Tao, Juan
    Pang, Xiaowen
    Yu, Jianbin
    Wang, Huiping
    Zhao, Yi
    Li, Chengxin
    Kang, Xiaojing
    Qin, Lanying
    Zhu, Xiaofang
    Su, Juan
    Li, Shanshan
    Yang, Chunjun
    Feng, Wenli
    Lei, Tiechi
    Jiang, Shan
    Fang, Ruihua
    Lin, Mao
    Lu, Qianjin
    Xu, Chunxing
    Wang, Wei
    Zhang, Jianzhong
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 (03) : 336 - 343
  • [24] Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study
    Gebauer, Kurt
    Spelman, Lynda
    Yamauchi, Paul S.
    Bagel, Jerry
    Nishandar, Tushar
    Crane, Michael
    Kopeloff, Iris
    Kothekar, Mudgal
    Yao, Siu-Long
    Sofen, Howard L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (01) : 91 - 99
  • [25] Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study
    Youn, Sang Woong
    Jo, Seong Jin
    Park, Chul Jong
    Kim, Dong Hyun
    Shin, Bong Seok
    Jeong, Ki Heon
    Bang, Chul Hwan
    Cross, Nancy
    Thirlwell, Jackie
    Hoepken, Bengt
    JOURNAL OF DERMATOLOGY, 2024,
  • [26] A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
    Gottlieb, A. B.
    Langley, R. G.
    Strober, B. E.
    Papp, K. A.
    Klekotka, P.
    Creamer, K.
    Thompson, E. H. Z.
    Hooper, M.
    Kricorian, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (03) : 649 - 657
  • [27] Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet Efficacy and Safety Results From REACH, a Randomized, Placebo-Controlled, Double-blind Trial
    Leonardi, Craig
    Langley, Richard G.
    Papp, Kim
    Tyring, Stephen K.
    Wasel, Norman
    Vender, Ronald
    Unnebrink, Kristina
    Gupta, Shiraz R.
    Valdecantos, Wendell C.
    Bagel, Jerry
    ARCHIVES OF DERMATOLOGY, 2011, 147 (04) : 429 - 436
  • [28] Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
    Papp, K. A.
    Langley, R. G.
    Sigurgeirsson, B.
    Abe, M.
    Baker, D. R.
    Konno, P.
    Haemmerle, S.
    Thurston, H. J.
    Papavassilis, C.
    Richards, H. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) : 412 - 421
  • [29] RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM IMMHANCE
    Blauvelt, Andrew
    Papp, Kim A.
    Gooderham, Melinda
    Langley, Richard G.
    Leonardi, Craig
    Lacour, Jean-Philippe
    Philipp, Sandra
    Tyring, Stephen
    Bukhalo, Michael
    Wu, Jashin J.
    Bagel, Jerry
    Frankel, Ellen H.
    Pariser, David
    Flack, Mary
    Scherer, Joseph
    Geng, Ziqian
    Gu, Yihua
    Camez, Anne
    Thompson, Elizabeth H. Z.
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 30 - 30
  • [30] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
    Armstrong, April W.
    Gooderham, Melinda
    Warren, Richard B.
    Papp, Kim A.
    Strober, Bruce
    Thaci, Diamant
    Morita, Akimichi
    Szepietowski, Jacek C.
    Imafuku, Shinichi
    Colston, Elizabeth
    Throup, John
    Kundu, Sudeep
    Schoenfeld, Steve
    Linaberry, Misti
    Banerjee, Subhashis
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : 29 - 39
12345